Home › Trials › NCT06869551

Evaluating Deucravacitinib for Juvenile Psoriatic Arthritis in Children

A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis

Phase 3 Interventional Bristol-Myers Squibb · NCT06869551

This study is testing if a new medication called Deucravacitinib can help children with juvenile psoriatic arthritis who haven't had success with other treatments.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment60 (estimated)
Ages5 Years to 17 Years
SexAll
SponsorBristol-Myers Squibb Industry-sponsored
Drugs / interventionsDeucravacitinib
Locations47 sites (Lancaster, California and 46 other locations)
Trial IDNCT06869551 on ClinicalTrials.gov

What this trial studies

This study evaluates the levels, efficacy, and safety of Deucravacitinib (BMS-986165) in children diagnosed with juvenile psoriatic arthritis. Participants must have at least three affected joints and have previously tried other medications without success. The study involves administering either Deucravacitinib or a placebo to assess its impact on the condition. The goal is to determine how well the drug works and its safety profile in a pediatric population.

Who should consider this trial

Good fit: Ideal candidates are children diagnosed with juvenile psoriatic arthritis who have not responded adequately to previous treatments.

Not a fit: Patients diagnosed with other types of juvenile idiopathic arthritis or those with a history of chronic eye inflammation may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new effective option for managing juvenile psoriatic arthritis in children.

How similar studies have performed: Other studies have shown promise with similar approaches, but the specific use of Deucravacitinib in this population is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria

* Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA).
* Participants must have at least three joints that are affected by arthritis.
* Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.

Exclusion Criteria

* Participants must not have been diagnosed with JPsA before 5 years of age.
* Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,
* Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Where this trial is running

Lancaster, California and 46 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Juvenile Psoriatic ArthritisJuvenile Idiopathic ArthritisPediatric PsADeucravacitinibBMS-986165
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.